Continuous Glucose Monitors Overestimate Glycemic Responses
By Elana Gotkine HealthDay Reporter
THURSDAY, March 6, 2025 -- Continuous glucose monitoring (CGM) can overestimate glycemic responses, according to a study published online Feb. 26 in The American Journal of Clinical Nutrition.
Katie M. Hutchins, from the University of Bath in the United Kingdom, and colleagues examined glycemic responses to different test foods/beverages using CGM versus capillary sampling among 15 healthy female and male participants (nine and six, respectively). Participants completed seven laboratory visits in a randomized crossover design with washout of ≥48 hours between visits. At each visit, participants consumed an oral carbohydrate challenge composed of either 50 g glucose or equivalent carbohydrate as a whole-fruit, blended-fruit, or commercial fruit smoothie.
The researchers found that compared with capillary estimates, CGM-estimated fasting and postprandial glucose concentrations were 0.9±0.6 and 0.9±0.5 mmol/L higher, respectively. There was variation in CGM bias by postprandial test, with the glycemic index for commercial fruit smoothie higher with CGM than capillary (69 versus 53). There was variation by participant in the differences in CGM versus capillary fasting glucose concentrations. Time >7.8 mmol/L was overestimated by about fourfold with CGM in unadjusted analyses; this overestimate was reduced to about twofold after adjustment for baseline differences.
"These data demonstrate that a CGM can overestimate postprandial glycemia, and to differing degrees across foods/beverages," the authors write. "Therefore, if accurate quantification of postprandial glycemia is the primary aim, then capillary blood should be the preferred method and CGM may not be suitable, at least with respect to the CGM device tested in the present study."
Several authors disclosed ties to the pharmaceutical, nutrition, and other industries; the data were supported by an unrestricted grant from Innocent Drinks.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted March 2025
Read this next
Real-World Weight Loss With Semaglutide, Tirzepatide Less Than That Seen in Clinical Trials
THURSDAY, June 12, 2025 -- For patients with obesity initiating pharmacotherapy with semaglutide or tirzepatide, weight loss at one year is 8.7 percent on average, which is lower...
Increasing Proportion of U.S. Adults Unaware They Have Hypertension
MONDAY, June 9, 2025 -- From 2013 to 2023, there was an increase in the proportion of U.S. adults who were unaware of having hypertension, according to a research letter published...
Finerenone + Empagliflozin Offers Greater Benefit in CKD, T2DM
MONDAY, June 9, 2025 -- For patients with chronic kidney disease and type 2 diabetes, combination finerenone plus empagliflozin leads to a greater reduction in the urinary...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.